Blog
RSS FeedPosted by Michael Wonder on 03 Aug 2020
Characteristics and strength of evidence of COVID-19 studies registered on ClinicalTrials.gov
27 July 2020 - The coronavirus disease 2019 (COVID-19) pandemic has led to a massive activation of clinical research. ...
Posted by Michael Wonder on 31 Jul 2020
Weighing the benefits and risks of proliferating observational treatment assessments: observational cacophony, randomised harmony
31 July 2020 - Amid the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, substantial effort is being directed toward ...
Posted by Michael Wonder on 20 Jul 2020
Trials of a vaccine and new drug raise hope of beating COVID-19
20 July 2020 - The latest tests with Oxford University’s vaccine, and interferon beta, look promising. ...
Posted by Michael Wonder on 15 Jul 2020
Improving clinical trial enrollment — In the COVID-19 era and beyond
15 July 2020 - More than 3 million people in the United States are known to have been infected with SARS-CoV-2. ...
Posted by Michael Wonder on 12 Jul 2020
COVID-19 is forcing us to rethink clinical trials for cancer treatments
9 July 2020 - Participation rates were already low, but the pandemic threatens to drive them even lower. ...
Posted by Michael Wonder on 18 Jun 2020
Clinical trial costs to develop a new drug may actually be rather modest — or so one study suggests
18 June 2020 - For years, the pharmaceutical industry has maintained that the costs to develop medicines accounts for rising ...
Posted by Michael Wonder on 04 Jun 2020
The Lancet, New England Journal retract COVID-19 studies, including one that raised safety concerns about malaria drugs
4 June 2020 - The Lancet, one of the world’s top medical journals, on Thursday retracted an influential study that ...
Posted by Michael Wonder on 25 May 2020
WHO pauses trial of hydroxychloroquine in COVID-19 patients due to safety concerns
26 May 2020 - The World Health Organisation has suspended testing the malaria drug hydroxychloroquine in COVID-19 patients due to ...
Posted by Michael Wonder on 05 May 2020
Pfizer and Biontech dose first participants in the U.S. as part of global COVID-19 MRNA vaccine development program
5 May 2020 - Pfizer and BioNTech ramping up manufacturing capabilities to further increase production capacity in 2020/2021. ...
Posted by Michael Wonder on 04 May 2020
Randomised clinical trials and COVID-19: managing expectations
4 May 2020 - Despite the millions of cases and hundreds of thousands of deaths that have occurred in this devastating ...
Posted by Michael Wonder on 23 Apr 2020
Increasing access to FDA inspection reports on irregularities and misconduct in clinical trials
23 April 2020 - Transparency related to clinical trial protocols and data has become the expected standard over the past 2 ...
Posted by Michael Wonder on 20 Apr 2020
Novartis to sponsor large clinical trial of hydroxychloroquine in hospitalised COVID-19 patients
20 April 2020 - Novartis has reached an agreement with the US FDA to proceed with a Phase III clinical trial ...
Posted by Michael Wonder on 18 Apr 2020
Finding effective treatments for COVID-19: scientific integrity and public confidence in a time of crisis
16 April 2020 - Everyone wants new treatments and vaccines to address the devastation of coronavirus disease 2019 (COVID-19). ...
Posted by Michael Wonder on 16 Apr 2020
A strategy for improving U.S. health care delivery — conducting more randomised, controlled trials
16 April 2020 - Despite the prominence of randomised, controlled trials in medical research, they have rarely been used to evaluate ...
Posted by Michael Wonder on 30 Mar 2020
FDA guidance on conduct of clinical trials of medical products during the COVID-19 pandemic
30 March 2020 - The U.S. FDA today issued an updated guidance, “Conduct of Clinical Trials of Medical Products during ...